The Seventh Circuit Court of Appeals recently ruled on a significant case involving five lawsuits against Mead Johnson & Company LLC and Abbott Laboratories. The court's decision, issued on July 28, 2026, addresses the legal concept of fraudulent joinder, which can affect a plaintiff's ability to pursue claims in federal court. This ruling impacts parents of premature infants who allege serious health issues tied to infant formula products.
The case, titled Terraine Abdullah v. Mead Johnson & Company LLC (Docket No. 25-2322), involves multiple plaintiffs who claim their children developed necrotizing enterocolitis (NEC) after being fed cow's milk-based formulas while hospitalized. The court's ruling has implications for how similar cases may be handled in the future, particularly regarding jurisdictional issues in federal court.
Background
The plaintiffs in this case are parents of premature infants who were treated at Pennsylvania Hospital in Philadelphia. They allege that their children developed NEC, a serious gastrointestinal disorder, after being fed either Similac or Enfamil formulas produced by Abbott and Mead Johnson. NEC can lead to severe health complications, including a high mortality rate.
The lawsuits were initially filed in Pennsylvania state court in March 2022 but were later removed to federal court by the defendants. The district court initially ruled that it lacked jurisdiction because the plaintiffs had viable claims against Pennsylvania Hospital, a non-diverse defendant. However, the defendants argued that the plaintiffs had fraudulently joined the hospital to defeat diversity jurisdiction.
After a series of legal maneuvers, including a remand to state court and subsequent removal back to federal court, the district court ultimately ruled that the plaintiffs had not demonstrated a genuine intention to pursue claims against Pennsylvania Hospital. This led to the certification of the issue for interlocutory appeal, allowing the Seventh Circuit to review the case.
The Ruling
The Seventh Circuit, led by Judge Ripple, reversed the district court's decision regarding fraudulent joinder. The court stated, "The district court’s view of the fraudulent joinder doctrine is not consistent with the case law of the Supreme Court or of the courts of appeals, including this court." The ruling emphasized that the determination of fraudulent joinder should be based on whether the plaintiffs have a reasonable chance of success against the non-diverse defendant, not on their litigation strategy or intent.
Judge Ripple further noted that the district court's approach improperly focused on the plaintiffs' litigation actions rather than the jurisdictional facts in their pleadings. The court concluded that the plaintiffs had a legitimate basis for their claims against Pennsylvania Hospital, and therefore, the cases should not have been removed based on fraudulent joinder.
Impact
This ruling has significant implications for similar cases involving claims against non-diverse defendants. It clarifies that a plaintiff's motives or litigation strategies cannot be used to establish fraudulent joinder. Instead, the focus should remain on the viability of the claims against the non-diverse defendant.
The decision reinforces the importance of protecting a plaintiff's choice of forum, particularly in cases involving complex medical issues and multiple defendants. It also sets a precedent for how courts may handle fraudulent joinder claims in the future, ensuring that plaintiffs have a fair opportunity to pursue their cases in the appropriate jurisdiction.
What's Next
The case has been remanded to the district court for further proceedings consistent with the Seventh Circuit's opinion. It remains to be seen whether the defendants will seek to appeal this ruling or if there are any related cases pending that may be affected by this decision.